Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.43 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.36 |
| ▸ | CLK1 | P49759 | 3/20 | 0.36 |
| ▸ | CLK3 | P49761 | 3/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.36 |
| ▸ | DYRK4 | Q9NR20 | 2/20 | 0.36 |
| ▸ | CLK2 | P49760 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15344908 | 0.92 | CYP11B2 (0.47) | CYP11B2MCHR1MCHR2KDM2BPDE10A | |
| SCHEMBL15340920 | 0.85 | CYP11B2 (0.45) | CYP11B2MCHR1MCHR2KDM2BPDE10A | |
| SCHEMBL15331887 | 0.80 | CYP11B2 (0.47) | CYP11B2MCHR1MCHR2CREBBPBRD4 | |
| SCHEMBL15340925 | 0.79 | CYP11B2 (0.44) | CYP11B2MCHR1MCHR2KDM2BPDE10A | |
| SCHEMBL15344137 | 0.77 | CYP11B2 (0.49) | CYP11B2CREBBPBRD4CDC7DYRK3 | |
| SCHEMBL26683815 | 0.75 | CRBN (0.49) | CYP11B2CREBBPBRD4DYRK3CLK1 | |
| SCHEMBL30449846 | 0.75 | CRBN (0.49) | CYP11B2CREBBPBRD4DYRK3CLK1 | |
| SCHEMBL3782201 | 0.74 | CYP17A1 (0.47) | CYP11B2MCHR1MCHR2 | |
| SCHEMBL29967049 | 0.74 | TERT (0.51) | CYP11B2KDM2BTRPA1NOTUM | |
| SCHEMBL20414628 | 0.71 | OTUD7B (0.42) | CYP11B2CREBBPBRD4DYRK3CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | CYP11B2 19/4885MCHR1 3991/4885MCHR2 4787/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | CYP11B2 19/4885MCHR1 3991/4885MCHR2 4787/4885 |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | CYP11B2 21/4885MCHR1 2520/4885MCHR2 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.